Consensus guidelines for the management and treatment of neuroendocrine tumors
Pancreas, ISSN: 0885-3177, Vol: 42, Issue: 4, Page: 557-577
2013
- 496Citations
- 295Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations496
- Citation Indexes487
- 487
- CrossRef312
- Policy Citations6
- Policy Citation6
- Clinical Citations3
- PubMed Guidelines3
- Captures295
- Readers295
- 295
- Mentions2
- News Mentions2
- News2
Most Recent News
Síndrome de feocromocitoma-paraganglioma tipo 5 asociado a mutacion en el complejo de la succinato deshidrogenasa tipo A (SDHA), a proposito de un caso/Pheochromocytoma-paraganglioma type 5 syndrome associated with mutation in the succinate dehydrogenase
Introduccion Los feocromocitomas (PCC) y paragangliomas (PGL) son tumores neuroendocrinos raros, productores de catecolaminas. Su incidencia anual combinada es de 0,6 casos por 100.000 personas
Article Description
ABSTRACT: Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician. Copyright © 2013 Lippincott Williams & Wilkins.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84876840005&origin=inward; http://dx.doi.org/10.1097/mpa.0b013e31828e34a4; http://www.ncbi.nlm.nih.gov/pubmed/23591432; http://Insights.ovid.com/crossref?an=00006676-201305000-00002; https://journals.lww.com/00006676-201305000-00002; https://dx.doi.org/10.1097/mpa.0b013e31828e34a4; https://journals.lww.com/pancreasjournal/Fulltext/2013/05000/Consensus_Guidelines_for_the_Management_and.2.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know